Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $2.44B |
| Gross Profit (TTM) | $2.81B |
| EBITDA | $1.56B |
| Operating Margin | 100.30% |
| Return on Equity | 13.80% |
| Return on Assets | 5.54% |
| Revenue/Share (TTM) | $5.67 |
| Book Value | $15.53 |
| Price-to-Book | 3.78 |
| Price-to-Sales (TTM) | 14.15 |
| EV/Revenue | 13.77 |
| EV/EBITDA | 19.77 |
| Quarterly Earnings Growth (YoY) | 23.20% |
| Quarterly Revenue Growth (YoY) | 11.00% |
| Shares Outstanding | $443.27M |
| Float | $413.50M |
| % Insiders | 6.51% |
| % Institutions | 86.26% |
Volatility is currently contracting
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RPRX and any ticker you trade — then tracks every position and per-strategy win rate.
